Connected Health Asia will bring together key decision makers from healthcare providers, researchers, mobile solution and technology providers and device manufacturer to discuss the critical issues in healthcare delivery and how it can be improved through connectivity – whether mobile, electronic or tele. The rising cost of healthcare and rapidly ageing society are driving the urgency for healthcare decision makers and providers to improve healthcare delivery while managing limited resources more effectively. Supported by fast developing technologies and applications, the connected health channel provides a unique opportunity for healthcare providers to reach out to patients directly, while enabling them to…

At IBC's 4th Annual BioProcess International™ China event, the goal is to bring China and the rest of the world together to explore the missing gaps in China's development, and to help bring China up-to-speed on critical areas such as cell line engineering, media development, analytical characterization strategies to establish similarity between a biosimilar and its originator drug, as well as design of multi-product facilities and implementation of single-use systems. Bringing together global leaders to provide you with proven scientific and technical strategies and innovations on: •Cell Line Engineering, Cell Culture and Media Development •Analytical Characterization, Comparability and Quality Assessment…

Being up-to-date with current requirements and understanding individual authority interpretation of guidelines is critical for successful product registration. The challenge in Asia is the frequency of changing regulations and increasing time-lag for regulatory approval – factors which can significantly impact on your time to market and bottom line. IBC’s Pharmaceutical Regulatory Asia Summit is the longest standing event of its kind in the region. In our 5 th year, we are emphasizing collaborations between industry and authority to expedite the approval of safe and effective drugs. In this event you will not be presented with a series of regulatory checklists…

The combined share of prescription drug spending in the US and Europe will shrink from 61% in 2005 to 44% by 2015. At the same time, spending in the emerging markets will grow from 12% in 2005 to 28% by 2015. - IMS Health report, 2011 With prolonged global economic crises and slowdown in the West, companies are increasingly looking towards the emerging markets. With a rapidly expanding, affluent (and ageing) population demanding greater access to affordable safe medicines, coupled with rising spending power, Southeast Asia presents the next growth area. While China and India have grabbed the attention of…

This is Asia’s first event dedicated to addressing the challenges faced by pharma professionals responsible for strategic sourcing, procurement and outsourcing. A must attend meeting for pharma executives in the business of or considering sourcing from Asia and outsourcing to Asia. It is estimated that China could be the world’s 2nd or 3rd largest pharmaceutical market by 2020 – Does your sourcing strategy give you a piece of the lucrative ‘China-pie’? Why You Must Attend This Year’s Event •The region’s first to market event focusing on the strategic needs of procurement and sourcing professionals specific to the pharma industry •The…